Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era.

doi:10.1158/1078-0432.CCR-11-3025

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Aug 2012

Cassier Philippe A, Fumagalli Elena, Rutkowski Piotr, Schöffski Patrick, Van Glabbeke Martine, Debiec-Rychter Maria, Emile Jean-François, Duffaud Florence, Martin-Broto Javier, Landi Bruno, Adenis Antoine, Bertucci François, Bompas Emmanuelle, Bouché Olivier, Leyvraz Serge, Judson Ian, Verweij Jaap, Casali Paolo, Blay Jean-Yves, Hohenberger Peter

Abstract excerpt

PURPOSE: Platelet-derived growth factor receptor-alpha (PDGFRA) mutations are found in approximately 5% to 7% of advanced gastrointestinal stromal tumors (GIST). We sought to extensively assess the activity of imatinib in this subgroup. EXPERIMENTAL DESIGN: We conducted an international survey among GIST referral centers to collect clinical data on patients with advanced PDGFRA-mutant GISTs treated with imatinib...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gastrointestinal Stromal Tumors

Share to Imatinib Mesylate

Share to Neoplasm Staging

Share to Piperazines

Share to Protein Kinase Inhibitors

Share to Pyrimidines

Share to Receptor, Platelet-Derived Growth Factor alpha

Source

Open in PubMed

Identifiers

PMID: 22718859
DOI: 10.1158/1078-0432.CCR-11-3025

Genes

PDGFRA

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era.PMID 22718859Read ↗

Efficacy of Imatinib in Patients with Platelet-Derived Growth Factor Receptor Alpha-Mutated Gastrointestinal Stromal Tumors.Semantic proximity Read ↗

Clinical characteristics and treatment outcome in a large multicentre observational cohort of PDGFRA exon 18 mutated gastrointestinal stromal tumour patients.Semantic proximity Read ↗

PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib.Semantic proximity Read ↗

Predicting Clinical Sensitivities of PDGFRA Exon 18 Mutations to Imatinib and Avapritinib to Optimize Gastrointestinal Stromal Tumor Treatment.Semantic proximity Read ↗

Molecular Advances in the Treatment of Advanced Gastrointestinal Stromal Tumor.Semantic proximity Read ↗

Clinicopathological and therapeutic analysis of PDGFRA mutated gastrointestinal stromal tumor.Semantic proximity Read ↗

Avapritinib in the treatment of PDGFRA exon 18 mutated gastrointestinal stromal tumors.Semantic proximity Read ↗

The GIST of Advances in Treatment of Advanced Gastrointestinal Stromal Tumor.Semantic proximity Read ↗

The Identity of PDGFRA D842V-Mutant Gastrointestinal Stromal Tumors (GIST)Semantic proximity Read ↗

Avapritinib in unresectable or metastatic gastrointestinal stromal tumor with PDGFRA exon 18 mutation: safety and efficacy.Semantic proximity Read ↗

Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib: An Exploratory Analysis of a Randomized Clinical Trial.Semantic proximity Read ↗

KIT, PDGFRA, and BRAF mutational spectrum impacts on the natural history of imatinib-naive localized GIST: a population-based study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.